- Home
- RERE vs ABUS Comparison
RERE vs ABUS Comparison
Compare RERE & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | ABUS |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.8M | 839.5M |
| IPO Year | 2021 | 2008 |
Fundamental Metrics
Financial Performance| Metric | RERE | ABUS |
|---|---|---|
| Price | $4.56 | $4.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 847.4K | ★ 1.3M |
| Earning Date | 05-19-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ 0.84 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $25.70 | N/A |
| Revenue Next Year | $22.93 | $239.71 |
| P/E Ratio | $34.57 | ★ $5.61 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $3.50 | $3.44 |
| 52 Week High | $6.47 | $5.38 |
Technical Indicators
Market Signals| Indicator | RERE | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 59.53 | 58.51 |
| Support Level | $4.31 | $4.11 |
| Resistance Level | $4.83 | $4.82 |
| Average True Range (ATR) | 0.18 | 0.16 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 68.75 | 90.65 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platforms PJT Marketplace and Paipai Marketplace. The Company's principal operations and geographic markets are in the People's Republic of China.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.